ALT Q1 2024 Earnings — Altimmune, Inc. Revenue & Financial Results | Market Cap Arena

ALTAltimmune, Inc.

$353M

Q1 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$5,000-76.2% YoY

Gross Profit

-$102,000-2040.0% margin

Operating Income

-$27M-535880.0% margin

Net Income

-$24M-487880.0% margin

EPS (Diluted)

$-0.34

QoQ Revenue Growth

-86.5%

Cash Flow

Operating Cash Flow

-$16M

Free Cash Flow

-$16M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$188M

Total Liabilities

$15M

Stockholders' Equity

$173M

Cash & Equivalents

$79M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$5,000	$21,000	-76.2%
Gross Profit	-$102,000	$21,000	-585.7%
Operating Income	-$27M	-$22M	-23.1%
Net Income	-$24M	-$20M	-21.5%